DAR Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 '50 Over 50: Innovation' List
Globe Newswire (Tue, 18-Aug 9:02 AM ET)
Daré Bioscience Announces New Equity Financing Agreements
TipRanks (Mon, 17-Aug 8:59 AM ET)
TipRanks (Sat, 15-Aug 2:30 PM ET)
Globe Newswire (Fri, 14-Aug 12:45 PM ET)
Globe Newswire (Thu, 13-Aug 4:01 PM ET)
Globe Newswire (Thu, 6-Aug 9:05 AM ET)
Globe Newswire (Tue, 28-Jul 8:34 AM ET)
Globe Newswire (Mon, 20-Jul 9:01 AM ET)
Dar Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Globe Newswire (Thu, 9-Jul 8:43 AM ET)
Dar Bioscience Announces Flora Sync LF5 Is Now Available Through Its Direct-to-Consumer Platform
Globe Newswire (Wed, 1-Jul 8:55 AM ET)
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Dare Bioscience trades on the NASDAQ stock market under the symbol DARE.
As of August 20, 2026, DARE stock price climbed to $0.83 with 41,539 million shares trading.
DARE has a beta of 3.58, meaning it tends to be more sensitive to market movements. DARE has a correlation of 0.16 to the broad based SPY ETF.
DARE has a market cap of $16.08 million. This is considered a Sub-Micro Cap stock.
Last quarter Dare Bioscience reported $187,546 in Revenue and -$.20 earnings per share. This beat revenue expectation by $185,546 and exceeded earnings estimates by $.10.
In the last 3 years, DARE traded as high as $9.19 and as low as $.75.
The top ETF exchange traded funds that DARE belongs to (by Net Assets): VTI, VXF, IWC.
DARE has underperformed the market in the last year with a price return of -58.9% while the SPY ETF gained +21.0%. DARE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -63.1% and -38.1%, respectively, while the SPY returned +4.8% and -0.4%, respectively.
DARE support price is $.77 and resistance is $.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DARE shares will trade within this expected range on the day.
